Literature DB >> 6486912

Parathyroid surgery in patients with renal failure.

F L Delmonico, C A Wang, N T Rubin, L S Fang, J T Herrin, A B Cosimi.   

Abstract

A subtotal parathyroidectomy was performed in 32 patients with hyperparathyroidism and renal dysfunction. Minimal long-term sequelae were observed [two patients with recurrent hyperparathyroidism (6.2%), one patient with persistent hypoparathyroidism (3.1%)]. This experience is compared with reports in the literature advocating total parathyroidectomy and autotransplantation. A subtotal parathyroidectomy remains the preferred approach at this institution. Patients with elevated alkaline phosphatase levels before surgery should be monitored carefully for early postoperative hypocalcemia. The low incidence (3.2%) of hyperparathyroidism observed in patients following successful renal transplantation indicates that hypercalcemic allograft recipients should be observed for at least 4 months before contemplating surgical intervention.

Entities:  

Mesh:

Year:  1984        PMID: 6486912      PMCID: PMC1250550          DOI: 10.1097/00000658-198411000-00015

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  9 in total

1.  Editorial: Hyperparathyroidism--too little, too much surgery?

Authors:  O Cope
Journal:  N Engl J Med       Date:  1976-07-08       Impact factor: 91.245

2.  Transplantation of the parathyroid glands: current status.

Authors:  S A Wells; A J Ross; J K Dale; R S Gray
Journal:  Surg Clin North Am       Date:  1979-02       Impact factor: 2.741

3.  Prevention and treatment of progressive secondary hyperparathyroidism in advanced renal failure.

Authors:  W J Johnson; R S Goldsmith; C D Arnaud
Journal:  Med Clin North Am       Date:  1972-07       Impact factor: 5.456

4.  The natural history and surgical treatment of hypercalcemia before and after renal transplantation.

Authors:  A G Diethelm; R P Edwards; J D Whelchel
Journal:  Surg Gynecol Obstet       Date:  1982-04

5.  Hyperparathyroidism during pregnancy.

Authors:  F L Delmonico; R M Neer; A B Cosimi; A B Barnes; P S Russell
Journal:  Am J Surg       Date:  1976-03       Impact factor: 2.565

6.  Total parathyroidectomy and autotransplantation in secondary hyperparathyroidism.

Authors:  M F Mozes; W D Soper; O Jonasson; G R Lang
Journal:  Arch Surg       Date:  1980-04

7.  Latent hypoparathyroidism in patients with autotransplanted parathyroid glands.

Authors:  H Salander; L E Tisell
Journal:  Am J Surg       Date:  1980-03       Impact factor: 2.565

8.  Total parathyroidectomy and autotransplantation of parathyroid tissue for renal hyperparathyroidism. A one- to six-year follow-up.

Authors:  M Rothmund; P K Wagner
Journal:  Ann Surg       Date:  1983-01       Impact factor: 12.969

9.  Long-term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation.

Authors:  S A Wells; J R Farndon; J K Dale; G S Leight; W G Dilley
Journal:  Ann Surg       Date:  1980       Impact factor: 12.969

  9 in total
  4 in total

1.  [Results of surgical therapy in renal hyperparathyroidism. Follow-up of 143 patients].

Authors:  C Dotzenrath; P E Goretzki; H D Roher
Journal:  Langenbecks Arch Chir       Date:  1996

2.  Postoperative hungry bone syndrome in patients with secondary hyperparathyroidism of renal origin.

Authors:  Melanie Goldfarb; Stephan S Gondek; Susan M Lim; Josephina C Farra; Vania Nose; John I Lew
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

3.  Prolonged hospital stay after parathyroidectomy for secondary hyperparathyroidism.

Authors:  Shih-Ping Cheng; Chien-Liang Liu; Han-Hsiang Chen; Jie-Jen Lee; Tsang-Pai Liu; Tsen-Long Yang
Journal:  World J Surg       Date:  2009-01       Impact factor: 3.352

4.  Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial.

Authors:  M Rothmund; P K Wagner; C Schark
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.